Otonomy Company Profile (NASDAQ:OTIC)

About Otonomy

Otonomy logoOtonomy, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics for diseases and disorders of the ear. The Company has developed a technology referred to as sustained-exposure that is designed to deliver drug that is retained in the ear for an extended period of time following a local administration. Its product candidates include OTIPRIO, OTO-104 and OTO-311. The Company's product candidate, OTIPRIO, is used for the treatment of pediatric patients with bilateral otitis media with effusion undergoing tympanostomy tube placement (TTP) surgery. Its product candidate, OTO-104, is a sustained-exposure formulation of the steroid dexamethasone in development for the treatment of Meniere's disease and other inner ear conditions. The Company's product candidate, OTO-311, is a sustained-exposure formulation of the N-Methyl-D-Aspartate (NMDA) receptor antagonist gacyclidine in development for the treatment of tinnitus.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: OTIC
  • CUSIP:
Key Metrics:
  • Previous Close: $16.85
  • 50 Day Moving Average: $17.63
  • 200 Day Moving Average: $15.79
  • 52-Week Range: $10.50 - $31.15
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.75
  • P/E Growth: -0.24
  • Market Cap: $508.33M
  • Outstanding Shares: 30,168,000
  • Beta: 2.91
  • Return on Equity: -42.24%
  • Return on Assets: -40.35%
  • Current Ratio: 22.95%
  • Quick Ratio: 22.87%
Additional Links:
Companies Related to Otonomy:

Analyst Ratings

Consensus Ratings for Otonomy (NASDAQ:OTIC) (?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $30.50 (81.01% upside)

Analysts' Ratings History for Otonomy (NASDAQ:OTIC)
DateFirmActionRatingPrice TargetDetails
8/15/2016Piper Jaffray Cos.Reiterated RatingOverweight$32.00View Rating Details
5/26/2016WallachBeth CapitalInitiated CoverageBuy$29.00View Rating Details
10/9/2015Bank of America Corp.UpgradeNeutral -> Buy$31.00View Rating Details
8/13/2015JPMorgan Chase & Co.Initiated CoverageHold$30.00View Rating Details
8/10/2015Sanford C. BernsteinUpgradeMarket Perform -> Outperform$30.00View Rating Details
2/4/2015SunTrust Banks Inc.Initiated CoverageBuy$47.00View Rating Details
2/4/2015Cowen and CompanyInitiated CoverageOutperform$55.00View Rating Details
(Data available from 10/22/2014 forward)


Earnings History for Otonomy (NASDAQ:OTIC)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/7/2016Q4($0.95)($0.87)ViewListenView Earnings Details
11/10/2015Q315($0.83)($0.57)ViewN/AView Earnings Details
8/12/2015Q116($0.67)($0.52)ViewN/AView Earnings Details
5/12/2015Q115($0.53)($0.52)ViewN/AView Earnings Details
3/18/2015Q415($0.64)($0.46)ViewListenView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Otonomy (NASDAQ:OTIC)
Current Year EPS Consensus Estimate: $-3.79 EPS
Next Year EPS Consensus Estimate: $-3.55 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.79)($0.79)($0.79)
Q2 20161($0.92)($0.92)($0.92)
Q3 20161($0.93)($0.93)($0.93)
Q4 20161($1.03)($1.03)($1.03)
(Data provided by Zacks Investment Research)


Dividend History for Otonomy (NASDAQ:OTIC)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Otonomy (NASDAQ:OTIC)
Insider Ownership Percentage: 17.90%
Institutional Ownership Percentage: 87.14%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/21/2015Carl LebelinsiderSell21,250$28.04$595,850.00View SEC Filing  
12/17/2015Paul E. CayerinsiderSell3,000$29.70$89,100.00View SEC Filing  
12/15/2015David Allen WeberCEOSell5,208$27.25$141,918.00View SEC Filing  
12/14/2015Robert Michael Savel IIinsiderSell5,000$26.00$130,000.00View SEC Filing  
11/30/2015Chau Quang KhuongDirectorSell67,106$28.93$1,941,376.58View SEC Filing  
11/24/2015Orbimed Advisors LlcDirectorSell200,800$28.56$5,734,848.00View SEC Filing  
11/19/2015Chau Quang KhuongDirectorSell138,398$28.62$3,960,950.76View SEC Filing  
11/17/2015Paul E. CayerinsiderSell3,000$28.69$86,070.00View SEC Filing  
11/16/2015David Allen WeberCEOSell5,208$28.57$148,792.56View SEC Filing  
11/13/2015David Allen WeberCEOSell10,416$30.95$322,375.20View SEC Filing  
11/11/2015David Allen WeberCEOSell5,208$24.95$129,939.60View SEC Filing  
11/11/2015Paul E. CayerCFOSell3,000$24.95$74,850.00View SEC Filing  
9/21/2015Carl LebelinsiderSell21,250$24.36$517,650.00View SEC Filing  
9/17/2015Paul E. CayerCFOSell3,000$24.95$74,850.00View SEC Filing  
9/15/2015David Allen WeberCEOSell5,216$24.95$130,139.20View SEC Filing  
9/14/2015Robert Michael Savel IIinsiderSell5,000$23.98$119,900.00View SEC Filing  
6/15/2015Robert Michael Savel IIInsiderSell25,000$23.73$593,250.00View SEC Filing  
8/19/2014A/S NovoInsiderBuy15,690$15.50$243,195.00View SEC Filing  
8/18/2014A/S NovoInsiderBuy171,875$16.00$2,750,000.00View SEC Filing  
8/18/2014Jay LichterDirectorSell50,001$16.00$800,016.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Otonomy (NASDAQ:OTIC)
News IconAnalyst Target Review on Otonomy, Inc. (NASDAQ:OTIC) - Recall News (NASDAQ:OTIC)
www.automobile-recalls.net - October 21 at 6:41 PM
News IconEarnings Take Center Stage; Analysts Weighing in on Otonomy, Inc. (NASDAQ:OTIC) - CSZ News (NASDAQ:OTIC)
cincysportszone.com - October 21 at 6:41 PM
investornewswire.com logoSell Recommendations For Otonomy, Inc. (NASDAQ:OTIC) At 0 - Investor Newswire (NASDAQ:OTIC)
www.investornewswire.com - October 19 at 11:47 AM
News IconLatest Analyst Ratings For Otonomy, Inc. (NASDAQ:OTIC) - The De Soto Edge (NASDAQ:OTIC)
www.desotoedge.com - October 18 at 11:56 AM
News IconTurning Heads Pre-Bell: Otonomy, Inc. (NASDAQ:OTIC) – Recall News - Recall News (NASDAQ:OTIC)
www.automobile-recalls.net - October 16 at 11:00 AM
News IconOtonomy, Inc. (NASDAQ:OTIC) Updated Broker Price Targets - The ... - The De Soto Edge (NASDAQ:OTIC)
www.desotoedge.com - October 16 at 11:00 AM
News IconSell-side Taking Aim at Shares of Otonomy, Inc. (NASDAQ:OTIC) - CSZ News (NASDAQ:OTIC)
cincysportszone.com - October 14 at 6:26 PM
insidermonkey.com logoOtonomy Inc (OTIC) Stock: Pivotal Data In Focus (NASDAQ:OTIC)
www.insidermonkey.com - October 13 at 10:18 AM
investornewswire.com logoOtonomy, Inc. (NASDAQ:OTIC) Sell Calls At 0 - Investor Newswire (NASDAQ:OTIC)
www.investornewswire.com - October 11 at 6:55 PM
marketexclusive.com logoOtonomy Inc (NASDAQ:OTIC): Pivotal Data In Focus - Market Exclusive (NASDAQ:OTIC)
marketexclusive.com - October 11 at 6:55 PM
marketexclusive.com logoOtonomy Inc (NASDAQ:OTIC): Pivotal Data In Focus (NASDAQ:OTIC)
marketexclusive.com - October 10 at 6:12 PM
investornewswire.com logoOtonomy, Inc. (NASDAQ:OTIC) Given A Rating Of 1.4 - Investor Newswire (NASDAQ:OTIC)
www.investornewswire.com - October 10 at 11:26 AM
News IconBroker Changes For Otonomy, Inc. (NASDAQ:OTIC) - NewsDen (NASDAQ:OTIC)
newsden.net - October 8 at 11:06 AM
News IconStock Update on Earnings & Estimates for Otonomy, Inc. (NASDAQ:OTIC) - CSZ News (NASDAQ:OTIC)
cincysportszone.com - October 8 at 11:06 AM
publicnow.com logoOtonomy Holds Investor and Analyst Day and Provides Corporate Update (NASDAQ:OTIC)
www.publicnow.com - October 7 at 11:49 AM
News IconOtonomy completes phase 2 study of Otiprio in paediatric patients with AOMT (NASDAQ:OTIC)
pharmabiz.com - October 6 at 12:09 PM
News IconLatest Analyst Ratings For Orion Engineered Carbons S.A (NYSE:OEC) (NASDAQ:OTIC)
www.desotoedge.com - October 5 at 11:54 AM
investornewswire.com logoOtonomy, Inc. (NASDAQ:OTIC) Sell Recommendations At 0 - Investor Newswire (NASDAQ:OTIC)
www.investornewswire.com - October 4 at 6:14 PM
streetinsider.com logoOtonomy (OTIC) Announces Completion of OTIPRIO Phase 2 in AOMT; Stat. Significant Data Noted - StreetInsider.com (NASDAQ:OTIC)
www.streetinsider.com - October 4 at 11:25 AM
publicnow.com logoOtonomy Successfully Completes Phase 2 Clinical Trial of OTIPRIO® in Pediatric Patients with Acute Otitis Media with Tympanostomy Tubes (NASDAQ:OTIC)
www.publicnow.com - October 4 at 11:25 AM
realistinvestor.com logoOtonomy, Inc. (NASDAQ:OTIC): Price Target Stands At $39 - RealistInvestor.com (NASDAQ:OTIC)
www.realistinvestor.com - September 30 at 11:55 AM
globenewswire.com logoOtonomy to Host Investor and Analyst Day on October 7, 2016 - GlobeNewswire (press release) (NASDAQ:OTIC)
globenewswire.com - September 29 at 11:47 AM
publicnow.com logoOtonomy to Host Investor and Analyst Day on October 7, 2016 (NASDAQ:OTIC)
www.publicnow.com - September 29 at 11:47 AM
investornewswire.com logoOtonomy, Inc. (NASDAQ:OTIC) Brokerage Rating At 1 - Investor Newswire (NASDAQ:OTIC)
www.investornewswire.com - September 28 at 11:42 AM
News IconOtonomy, Inc. (NASDAQ:OTIC) Analyst Review - NewsDen (NASDAQ:OTIC)
newsden.net - September 28 at 11:42 AM
News IconOtonomy Incorporated (NASDAQ:OTIC) Sellers Increased By 2.89% Their Shorts - Post News (NASDAQ:OTIC)
www.kentuckypostnews.com - September 25 at 5:54 PM
kcregister.com logoWatch List: Otonomy, Inc. (NASDAQ:OTIC), OneBeacon Insurance Group, Ltd. (NYSE:OB), KeyCorp. (NYSE:KEY ... - KC Register (NASDAQ:OTIC)
www.kcregister.com - September 21 at 10:44 AM
investornewswire.com logoShares Of Otonomy, Inc. (NASDAQ:OTIC) Expected To Hit $55 - Investor Newswire (NASDAQ:OTIC)
www.investornewswire.com - September 21 at 10:43 AM
News IconOtonomy completes open-label phase 3b study of Otiprio in patients with history of otitis media requiring tympanostomy tubes (NASDAQ:OTIC)
www.pharmabiz.com - September 19 at 11:09 AM
realistinvestor.com logoResearch Analysts Set Otonomy, Inc. (NASDAQ:OTIC)'s Price Target At $39 - RealistInvestor.com (NASDAQ:OTIC)
www.realistinvestor.com - September 16 at 6:27 PM
rttnews.com logoARLZ Gets FDA Nod, ACRX Scores Hat Trick, OTIC On Watch, No Relief For NVAX (NASDAQ:OTIC)
www.rttnews.com - September 16 at 10:07 AM
publicnow.com logoOtonomy Successfully Completes Open-Label Clinical Trial for OTIPRIO® in Patients with History of Otitis Media Requiring Tympanostomy Tubes (NASDAQ:OTIC)
www.publicnow.com - September 15 at 10:06 AM
News IconSell-side is Weighing in on Otonomy, Inc. (NASDAQ:OTIC) Earnings & Targets - Frisco Fastball (NASDAQ:OTIC)
friscofastball.com - September 14 at 6:45 PM
streetinsider.com logoOtonomy (OTIC) to Present OTIPRIO Phase 2 Data in AOE at American Academy of Otolaryngology - StreetInsider.com (NASDAQ:OTIC)
www.streetinsider.com - September 13 at 11:32 AM
finance.yahoo.com logoOtonomy Announces OTIPRIO® Data Presentation and Symposium at American Academy of Otolaryngology - Head and Neck Surgery Foundation Annual Meeting (NASDAQ:OTIC)
finance.yahoo.com - September 13 at 11:32 AM
News IconAnalysts Place Otonomy, Inc. (NASDAQ:OTIC) Under the Lens of the Microscope - Post News (NASDAQ:OTIC)
www.kentuckypostnews.com - September 12 at 6:21 PM
investornewswire.com logoOtonomy, Inc. (NASDAQ:OTIC) Reported An Earnings Surprise Of -5.38 Percent - Investor Newswire (NASDAQ:OTIC)
www.investornewswire.com - September 12 at 6:21 PM
fidaily.com logoOtonomy, Inc. (NASDAQ:OTIC) Trading Down - Insider Trading Activity - Finance Daily (NASDAQ:OTIC)
www.fidaily.com - September 9 at 6:16 PM
finance.yahoo.com logoOtonomy to Present at Baird Global Healthcare Conference (NASDAQ:OTIC)
finance.yahoo.com - September 1 at 9:48 AM
investornewswire.com logoOtonomy, Inc. (NASDAQ:OTIC) Gets 0 Recommendations To Sell - Investor Newswire (NASDAQ:OTIC)
www.investornewswire.com - August 24 at 9:46 AM
News IconAuris plunges as Keyzilen falls short in phase III tinnitus trial (NASDAQ:OTIC)
www.bioworld.com - August 19 at 9:44 AM
investornewswire.com logoWill Otonomy, Inc. (NASDAQ:OTIC) Hit $55 Price Target? - Investor Newswire (NASDAQ:OTIC)
www.investornewswire.com - August 18 at 9:46 AM
finance.yahoo.com logoEdited Transcript of OTIC earnings conference call or presentation 4-Aug-16 8:30pm GMT (NASDAQ:OTIC)
finance.yahoo.com - August 15 at 7:01 PM
finance.yahoo.com logoOTONOMY, INC. Financials (NASDAQ:OTIC)
finance.yahoo.com - August 12 at 6:50 PM
capitalcube.com logoETF’s with exposure to Otonomy, Inc. : August 11, 2016 (NASDAQ:OTIC)
www.capitalcube.com - August 11 at 7:10 PM
capitalcube.com logoOtonomy, Inc. breached its 50 day moving average in a Bullish Manner : OTIC-US : August 10, 2016 (NASDAQ:OTIC)
www.capitalcube.com - August 10 at 9:48 AM
rttnews.com logoEGLT Gets FDA Panel Nod, NXTM On A High, BDSI Ahead Of Schedule (NASDAQ:OTIC)
www.rttnews.com - August 5 at 9:46 AM
biz.yahoo.com logoOtonomy Inc Earnings Call (Q2 2016) (NASDAQ:OTIC)
biz.yahoo.com - August 5 at 9:46 AM
sg.finance.yahoo.com logoOtonomy reports 2Q loss (NASDAQ:OTIC)
sg.finance.yahoo.com - August 5 at 9:45 AM
twst.com logoOtonomy Inc.: Otonomy Reports Second Quarter 2016 Financial Results and Provides Corporate Update (NASDAQ:OTIC)
www.twst.com - August 4 at 7:08 PM


Otonomy (NASDAQ:OTIC) Chart for Saturday, October, 22, 2016

Last Updated on 10/22/2016 by MarketBeat.com Staff